Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

NewLink, Genentech Hook Up

by Rick Mullin
October 27, 2014 | A version of this story appeared in Volume 92, Issue 43

Immunotherapeutics specialist NewLink Genetics has licensed NLG919, its indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to Genentech. NewLink will receive $150 million up front and is eligible to receive milestone payments and royalties. Genentech also will fund future R&D and manufacturing. IDO pathway inhibitors are small-molecule immune checkpoint inhibitors that can complement Genentech antibodies being developed as immunotherapies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.